Skip to content

Evaluation of allergenicity of partially hydrolyzed soy formula and oral immunotherapy using the formula in children with soybean allergy

Evaluation of allergenicity of partially hydrolyzed soy formula and oral immunotherapy using the formula in children with soybean allergy - Allergenicity of partially hydrolyzed soy formula and Immunotherapy for soybean allergy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000030059
Enrollment
10
Registered
2017-11-22
Start date
2017-11-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

food allergy

Interventions

soy milk oral food challenge (1-2-5-10-20 ml, 30 min interval) and partially hydrolyzed soy formula oral food challenge (2-4-10-20-40 ml, 30 min interval ) in the patient with soybean allergy

Sponsors

Aichi Children's Health and Medical Center
Lead Sponsor
Department of Pediatrics, Fujita Health University Department of Nutrition Management, Nagoya University of Arts and Sciences
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patient with positive result for soy milk oral food challenge test(1-2-5-10-20 ml, 30 min interval)

Exclusion criteria

Exclusion criteria: patients during oral immunotherapy for other food antigen. patients with severe comorbidity. patients with uncontrollable asthma or atopic dermatitis. patients who have developed anaphylaxis by soy allergen within one year before the oral food challenge. patients whom the doctor asses ineligible.

Design outcomes

Primary

MeasureTime frame
The threshold dose of soy milk and partially hydrolyzed soy formula in the patient with soybean allergy

Secondary

MeasureTime frame
Efficacy and safety at 6 months of oral immunotherapy using partially hydrolyzed soy formula. Change of the basophil activation by oral immunotherapy using partially hydrolyzed soy formula. IgE-immunoblotting and ELISA using the serum of the patients soybeans allegy.

Countries

Japan

Contacts

Public ContactIwao Tajima

Aichi Children's Health and Medical Center Department of Allergy

iwao_tajima@sk00106.achmc.pref.aichi.jp0562-43-0500

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026